FMP

FMP

Enter

MOLN - Molecular Partners A...

Financial Summary of Molecular Partners AG(MOLN), Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discove

photo-url-https://financialmodelingprep.com/image-stock/MOLN.png

Molecular Partners AG

MOLN

NASDAQ

Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema; and MP0420, a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus. The company develops MP0310, which is in Phase Ia clinical trials for immuno-oncology; MP0317, a tumor-localized immune agonist that activates immune cells in the tumor, which is in Phase I clinical trials; and MP0274 that is in Phase I clinical trials for HER2-positive cancers. It also develops MP0423 for treating COVID-19; MP0533, a CD3 T cell candidate for acute myeloid leukemia; and MP0250 for vascular endothelial growth factor, hepatocyte growth factor, and human serum albumin to increase half-life. Molecular Partners AG has agreements and collaboration with Novartis AG to develop, manufacture, and commercialize DARPin-conjugated radioligand therapies; Amgen SA; Allergan, Inc.; and discovery alliance with AbbVie Inc. in ophthalmology, as well as other third-party collaborators. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland.

3.58 USD

-0.14 (-3.91%)

About

ceo

Dr. Patrick Amstutz Ph.D.

sector

Healthcare

industry

Biotechnology

website

https://www.molecularpartners.com

exchange

NASDAQ

Description

Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema; and MP0420, a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus. The company develops MP0310, which is in Phase Ia clinical trials for immuno-oncology; MP0317, a tumor-localized immune agonist that activates immune cells in the tumor, which is in Phase I clinical trials; and MP0274 that is in P...

CIK

0001745114

ISIN

US60853G1067

CUSIP

60853G106

Address

Wagistrasse 14

Phone

41 44 755 77 00

Country

CH

Employee

167

IPO Date

Jun 16, 2021

Summary

CIK

0001745114

Exchange

NASDAQ

Industry

Biotechnology

Sector

Healthcare

CUSIP

60853G106

ISIN

US60853G1067

Country

CH

Price

3.58

Beta

0.8

Volume Avg.

3.49k

Market Cap

118.79M

Shares

-

52-Week

3.32-7.32

DCF

4.95

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

-1.72

P/B

-

Website

https://www.molecularpartners.com

Historical Prices

We are unable to load the chart at this time.

fmp-logo

Financial Statement

We are unable to load the chart at this time.

fmp-logo

Earnings

We are unable to load the chart at this time.

fmp-logo

Upgrades and Downgrades

We are unable to load this data!

fmp-logo

People Also Watch

page loading card

Latest MOLN News

It looks like there's no news available.

fmp-logo
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep